Genprex (GNPX)

• Market cap: $4.59M
• 1 day: -0.98%
• 5 days: -9.82%
• 1 month: -15.83%
• 3 months: -51.21%
• 6 months: -82.06%
• Year to date: 12.85%
• 1 year: -91.42%
• 5 years: -99.99%
• 10 years: -99.98%
• Sector: Healthcare
• Industry: Biotechnology

About: Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

Employees: 13